Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

Recordati Rare Diseases Inc. today announced the presentation of new data related to its growing portfolio of treatments for rare hematologic disorders at the 67th American Society of Hematology (ASH) ...

The European medicines regulator said that a higher rate of death and disease complications in recent trials meant the ...

Azlind Davis' immune system was mistakenly attacking her red blood cells, causing anemia. A blood drive is scheduled for Oct.

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...

The drug, dubbed ianalumab, both depletes B cells and deactivates those remaining, Thomas Grader-Beck, MD, of Johns Hopkins ...

Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

Copper is an essential trace mineral vital for energy production, connective tissue integrity, and brain health, helping to ...

Detailed price information for 60 Degrees Pharmaceuticals Inc (SXTP-Q) from The Globe and Mail including charting and trades.

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for zaltenibart. Click for my OMER update.